CSI Market
Sign In | Register

Rocket Pharmaceuticals Inc (RCKT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RCKT quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Rocket Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-223.12
Depreciation & amortization8.87
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation37.06
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Fair Value Adjustment Of Convertible Notes Redemption Rights Derivative-
Noncash Interest Expense-
Reduction Of Lease Liability-
Amortization Of Operating Lease Right Of Use Assets-
Increase Decrease In Operating Lease Liabilities-
Retirement Of Treasury Stock Noncash-
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Property Plant And Equipment Write Down-
Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments-6.97
Increase Decrease In Operating Lease Liability-
Debt Conversion Converted Instrument Amount-
Increase Decrease In Operating Lease Liability And Right Of Use Assets Net0.05
Adjustment Of Right Of Use Assets2.15
Increase Decrease In Finance Lease Liabilities0.04
Income taxes0.00
Unrealized Gain (Loss) on Investments-0.10
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-10.35
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.09
Other Working Capital-0.08
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.36
Discontinued operations0.00
Net Cash flow from Operating Activities-190.01
Investing Activities
Capital Expenditures-0.44
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments380.76
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments Of Security Deposits-
Payments To Acquire Right Of Use Asset-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-276.55
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities103.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.07
Net Proceeds From Underwritten Offering Of Debt-
Payments For Repurchase Treasury Stock-
Return Of Related Party Short Swing Profits0.22
Payments For Finance Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.15
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-190.45
Total Cash Flow-86.10
4 historic quarters locked

Sign in to unlock the full Rocket Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Rocket Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: rckt-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-076551

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License